Adenocarcinoma of the Gastroesophageal Junction Clinical Trial
Official title:
A Phase 2 Study of AZD0530 in Patients With Metastatic or Locally Advanced Gastric Carcinoma
Verified date | July 2018 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 21 |
Est. completion date | April 2012 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ) - Tumors of the GEJ must be sub-specified as type I, II, or III using the Siewert classification - Metastatic or locally advanced disease - Patients with local/regional disease only, must have unresectable disease - Measurable disease, defined as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral computed tomography (CT) scan - No known brain metastases - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy > 3 months - Platelet count = 100,000/mm³ - Leukocytes = 3,000/mm³ - Absolute neutrophil count = 1,500/mm³ - Hemoglobin > 9 g/dL - Total bilirubin normal - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 times upper limit of normal - Creatinine normal OR creatinine clearance = 60 mL/min - Urine protein creatinine ratio < 1.0 OR urine protein < 1,000 mg by 24-hour urine collection Exclusion Criteria: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No condition that potentially impairs the ability to swallow or absorb AZD0530, including any of the following: - Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation - Active peptic ulcer disease - Short gut syndrome - Malabsorption syndrome of any type - Total or partial bowel obstruction - Inability to tolerate oral medications - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530 - No QTc prolongation (defined as a QTc interval = 460 msec) or other significant electrocardiogram (ECG) abnormalities - No poorly controlled hypertension (i.e., systolic blood pressure [BP] = 140 mm Hg or diastolic BP = 90 mm Hg) - No history of ischemic heart disease, including myocardial infarction - No concurrent cardiac dysfunction including, but not limited to, any of the following: - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia - No other concurrent uncontrolled illness, including ongoing or active infection or psychiatric illness/social situations, that would limit compliance with study requirements - Prior chemotherapy allowed provided it was administered as part of initial curative intent therapy (i.e., neoadjuvant therapy, adjuvant therapy and/or concurrently with radiotherapy) in combination with surgery - At least 4 weeks since prior chemotherapy - At least 4 weeks since prior and no more than 1 line of palliative chemotherapy for advanced disease - At least 4 weeks since prior radiotherapy and recovered - At least 4 weeks since prior major surgery and recovered - No cytochrome 450 3A4 (CYP3A4) active agents or substances for = 7 days before, during, and for = 7 days after completion of study treatment - No other concurrent investigational agents - No other concurrent anticancer therapy - No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients |
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Ontario |
Canada | McGill University Department of Oncology | Montreal | Quebec |
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | Hamilton Medical Center | Dalton | Georgia |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) | PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. CR is defined as disappearance of all non-target lesions and normalization of tumor marker level. | Every 2 weeks for the first 4 weeks, and then every 4-8 weeks thereafter, for at least 16 weeks up to 37 weeks | |
Primary | Prolonged Stable Disease Rate (Defined as Stable Disease for = 16 Weeks) | Every 2 weeks for the first 4 weeks, and then every 4-8 weeks thereafter, for at least 16 weeks up to 37 weeks | ||
Secondary | Time to Progression | Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions,or a measurable increase in non-target lesions, or the appearance of new lesions. | Up to 1 year (median, 6 month, 1-year) | |
Secondary | Progression-free Survival | Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. | Measured from the date of enrollment to progression, death or last contact, or last tumor assessment before the start of further anti-tumor therapy | |
Secondary | Median Survival | Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. | Up to 1 year | |
Secondary | Overall Survival | The Kaplan-Meier method will be used to estimate overall and time to progression estimates. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. | Up to 1 year (median, 6 months, and 1 year) | |
Secondary | Highest Grade Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Version 3.0. | Toxicities will be graded using the National Cancer Institute (NCI) Common Toxicity Criteria Version 3.0. | Weekly during treatment | |
Secondary | Patient Tolerability | Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. | Weekly during treatment | |
Secondary | Association Between Correlative Markers and Clinical Outcomes | Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. | At baseline, 6 months, and then at 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02234180 -
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
|
Phase 2 | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT01178944 -
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT00991952 -
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Terminated |
NCT00732745 -
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 1 | |
Completed |
NCT00253370 -
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
Recruiting |
NCT04773769 -
Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas
|
N/A | |
Completed |
NCT02918162 -
Perioperative Chemo and Pembrolizumab in Gastric Cancer
|
Phase 2 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Active, not recruiting |
NCT01939275 -
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
|
N/A | |
Completed |
NCT02013154 -
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
|
Phase 1 | |
Completed |
NCT01107639 -
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
|
Phase 3 | |
Completed |
NCT01855854 -
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
|
Phase 2 | |
Withdrawn |
NCT02344810 -
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01243398 -
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
|
Phase 3 | |
Completed |
NCT00084617 -
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Completed |
NCT01360086 -
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction
|
Phase 2 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00045526 -
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
|
Phase 2 |